{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:30Z","timestamp":1791331710081,"version":"4.3.1"},"reference-count":329,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:p>\n                    The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of\n                    <jats:italic>in vitro<\/jats:italic>\n                    activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR)\n                    <jats:italic>Enterobacterales<\/jats:italic>\n                    and\n                    <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/cmr.00115-20","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T08:59:37Z","timestamp":1604998777000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":507,"title":["New \u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor Combinations"],"prefix":"10.1128","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-9791","authenticated-orcid":false,"given":"Dafna","family":"Yahav","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Giske","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alise","family":"Gr\u0101matniece","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden"},{"name":"Pauls Stradins University Hospital, University of Latvia, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrietta","family":"Abodakpi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent H.","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel"},{"name":"Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.515588"},{"key":"e_1_3_2_5_2","volume-title":"Approval package for application number 206829Orig1s000","author":"FDA","year":"2014","unstructured":"FDA. 2014. Ceftolozane-tazobactam. Center for Drug Evaluation and Research. Approval package for application number 206829Orig1s000. FDA, Silver Spring, MD."},{"key":"e_1_3_2_6_2","volume-title":"AVYCAZ injection","author":"FDA","year":"2015","unstructured":"FDA. 2015. Ceftazidime-avibactam. Center for Drug Evaluation and Research. Approval package for application number 206494Orig1s000. AVYCAZ injection. FDA, Silver Spring, MD."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964434"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.06.015"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.3.291.32110"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02747-15"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01052-17"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06113-11"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0705-y"},{"key":"e_1_3_2_15_2","volume-title":"Application number 209776Orig1s000, clinical pharmacology and biopharmaceutics review(s)","author":"FDA","year":"2017","unstructured":"FDA. 2017. Meropenem-vaborbactam. Center for Drug Evaluation and Research. Application number 209776Orig1s000, clinical pharmacology and biopharmaceutics review(s). FDA, Silver Spring, MD."},{"key":"e_1_3_2_16_2","volume-title":"Application number 212819Orig1s000, multi-discipline review","author":"FDA","year":"2018","unstructured":"FDA. 2018. Imipenem-relebactam. Center for Drug Evaluation and Research. Application number 212819Orig1s000, multi-discipline review. FDA, Silver Spring, MD."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2019.05.006"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2155-1"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa118"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S40698"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04191-14"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky279"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02019-15"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-17"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01682-10"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.Supplement_1.S110"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-13"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2016.09.013"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.033"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02083-16"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx438"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4409-1"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.015"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-16"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00020"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02286-15"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.04.012"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz456"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02369-16"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1155"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00264-16"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku025"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku551"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05024-14"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02969-15"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.06.007"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.02.022"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.05.001"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00989-17"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00537-17"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-17"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx179"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02101-17"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky082"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa241"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx298"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S53874"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000028"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04238-14"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-17"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw398"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv004"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq306"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.10.173"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00408-18"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx066"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.08.020"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00451-17"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.011"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw636"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-17"},{"key":"e_1_3_2_77_2","volume-title":"Avycaz (package insert)","author":"Allergan, Inc","year":"2019","unstructured":"Allergan, Inc. 2019. Avycaz (package insert). Allergan, Inc., Irvine, CA."},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02497-17"},{"key":"e_1_3_2_79_2","volume-title":"European Medicines Agency assessment report","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. 2016. Zavicefta, INN-ceftazidime\/avibactam. European Medicines Agency assessment report. European Medicines Agency, Amsterdam, Netherlands."},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky124"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.64.03.253"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.09.007"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.07.004"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky204"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.010"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.07.010"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix783"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02320-19"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00449-17"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.08.025"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002392"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002395"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002344"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00528-19"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02213-17"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13082"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1261-y"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky558"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13034"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky136"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01595-19"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx306"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx307"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1701102"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2019.1709363"},{"key":"e_1_3_2_111_2","unstructured":"ClinicalTrials.gov. 2019. Impact of ceftazidime\/avibactam treatment vs better available therapy on mortality of patients with infections caused by carbapenem-resistant enterobacteria (CAVICOR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04167228."},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.05.019"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04498-14"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku184"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.004"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz147"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S175679"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01404-13"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx136"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105887"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02253-13"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-10"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.501"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.11.021"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.09.016"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx468"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.01.015"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02431-18"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1556\/1886.2019.00001"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix182"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9095203"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx424"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02085-18"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky393"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02462-13"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02291-19"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01390-y"},{"key":"e_1_3_2_139_2","volume-title":"Zerbaxa (package insert)","author":"Merck & Co., Inc","year":"2019","unstructured":"Merck & Co., Inc. 2019. Zerbaxa (package insert). Merck & Co., Inc., Kenilworth, NJ."},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02578-18"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00049-14"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.11.015"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz816"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa003"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw053"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.10.009"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.10.012"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002170"},{"key":"e_1_3_2_153_2","unstructured":"ClinicalTrials.gov. 2017. MK-7625A versus meropenem in pediatric participants with complicated urinary tract infection (cUTI) (MK-7625A-034). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03230838."},{"key":"e_1_3_2_154_2","unstructured":"ClinicalTrials.gov. 2017. MK-7625A plus metronidazole versus meropenem in pediatric participants with complicated intra-abdominal infection (cIAI) (MK-7625A-035). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03217136."},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8020067"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001228"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14388"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw486"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.001"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2434-5"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz011"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2414-9"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky423"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.01.010"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02136-16"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3361-0"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1133-5"},{"key":"e_1_3_2_168_2","unstructured":"ClinicalTrials.gov. 2018. Comparative study to determine the efficacy safety and tolerability of ceftolozane-tazobactam. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03485950."},{"key":"e_1_3_2_169_2","unstructured":"ClinicalTrials.gov. 2019. Ceftolozane\/tazobactam (MK-7625A) plus metronidazole versus meropenem for participants with complicated intra-abdominal infection (MK-7625A-015) (7625ACNPhase3). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03830333."},{"key":"e_1_3_2_170_2","unstructured":"ClinicalTrials.gov. 2020. Ceftolozane-tazobactam versus meropenem for ESBL and AmpC-producing Enterobacterales bloodstream infection (MERINO III). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04238390."},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00711-16"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00567-17"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt118"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-15"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.08.011"},{"key":"e_1_3_2_177_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-17"},{"key":"e_1_3_2_178_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01439-17"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.02.021"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1207834"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01904-17"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.09.017"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02177-19"},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01969-17"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01551-18"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0851-9"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.930"},{"key":"e_1_3_2_188_2","volume-title":"VABOMERE (package insert)","author":"Melinta Therapeutics, Inc","year":"2018","unstructured":"Melinta Therapeutics, Inc. 2018. VABOMERE (package insert). Melinta Therapeutics, Inc., Morristown, NJ."},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01713-15"},{"key":"e_1_3_2_190_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0438"},{"key":"e_1_3_2_191_2","unstructured":"ClinicalTrials.gov. 2016. Dose-finding pharmacokinetics and safety of VABOMERE in pediatric subjects with bacterial infections (TANGOKIDS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02687906."},{"key":"e_1_3_2_192_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2187"},{"key":"e_1_3_2_193_2","volume-title":"Meropenem-vaborbactam versus best-available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in patients with cancer, abstract P0285","author":"Viale P","year":"2018","unstructured":"Viale P. 2018. Meropenem-vaborbactam versus best-available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in patients with cancer, abstract P0285. 28th European Society of Clinical Microbiology and Infectious Diseases, Madrid, Spain."},{"key":"e_1_3_2_194_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0214-1"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00981-y"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101650"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1131"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky346"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz103"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02255-19"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01694-17"},{"key":"e_1_3_2_202_2","unstructured":"ClinicalTrials.gov. 2016. A study of meropenem-vaborbactam versus piperacillin\/tazobactam in participants with hospital-acquired and ventilator-associated bacterial pneumonia (TANGOIII). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03006679."},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt178"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2375-0"},{"key":"e_1_3_2_205_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-019-1522-7"},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2011.10.001"},{"key":"e_1_3_2_207_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00533-18"},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05927-11"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00169-18"},{"key":"e_1_3_2_210_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-17"},{"key":"e_1_3_2_211_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00548-15"},{"key":"e_1_3_2_212_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00564-19"},{"key":"e_1_3_2_213_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03517-y"},{"key":"e_1_3_2_214_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02209-16"},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.022"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.10.028"},{"key":"e_1_3_2_217_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02623-18"},{"key":"e_1_3_2_219_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-18"},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz354"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02165-19"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz114"},{"key":"e_1_3_2_223_2","volume-title":"RECARBRIO (package insert)","author":"Merck & Co., Inc","year":"2019","unstructured":"Merck & Co., Inc. 2019. RECARBRIO (package insert). Merck & Co., Inc., Kenilworth, NJ."},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02323-17"},{"key":"e_1_3_2_225_2","volume-title":"Recarbrio (imipenem\/cilastatin\/relebactam) - an overview of Recarbrio and why it is authorised in the EU","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. 2020. Recarbrio (imipenem\/cilastatin\/relebactam) - an overview of Recarbrio and why it is authorised in the EU. European Medicines Agency, Amsterdam, Netherlands."},{"key":"e_1_3_2_226_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx139"},{"key":"e_1_3_2_227_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-16"},{"key":"e_1_3_2_228_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz530"},{"key":"e_1_3_2_229_2","unstructured":"ClinicalTrials.gov. 2019. Safety tolerability efficacy and pharmacokinetics of imipenem\/cilastatin\/relebactam (MK-7655A) in pediatric participants with Gram-negative bacterial infection (mk-7655a-021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03969901."},{"key":"e_1_3_2_230_2","unstructured":"ClinicalTrials.gov. 2017. Efficacy and safety of imipenem+cilastatin\/relebactam (MK-7655A) in Japanese participants with complicated intra-abdominal infection or complicated urinary tract infection (MK-7655A-017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03293485."},{"key":"e_1_3_2_231_2","unstructured":"ClinicalTrials.gov. 2018. Imipenem\/cilastatin\/relebactam (MK-7655A) versus piperacillin\/tazobactam in participants with hospital-acquired or ventilator-associated bacterial pneumonia (MK-7655A-016). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03583333."},{"key":"e_1_3_2_232_2","unstructured":"ClinicalTrials.gov. 2015. Imipenem\/relebactam\/cilastatin versus piperacillin\/tazobactam for treatment of participants with bacterial pneumonia (MK-7655A-014) (RESTORE-IMI 2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02493764."},{"key":"e_1_3_2_233_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx360"},{"key":"e_1_3_2_234_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02409-16"},{"key":"e_1_3_2_235_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1410284"},{"key":"e_1_3_2_236_2","doi-asserted-by":"publisher","DOI":"10.5799\/ahinjs.02.2012.03.0049"},{"key":"e_1_3_2_237_2","unstructured":"ClinicalTrials.gov. 2018. Study of cefepime-tazobactam (FEP-TAZ) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03630081."},{"key":"e_1_3_2_238_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_2_239_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00607-19"},{"key":"e_1_3_2_240_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_2_241_2","unstructured":"ClinicalTrials.gov. 2018. Safety and efficacy study of cefepime-AAI101 in the treatment of complicated urinary tract infections. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03687255."},{"key":"e_1_3_2_242_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00091"},{"key":"e_1_3_2_243_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.105863"},{"key":"e_1_3_2_244_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx050"},{"key":"e_1_3_2_245_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz294"},{"key":"e_1_3_2_246_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8010032"},{"key":"e_1_3_2_247_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00733-19"},{"key":"e_1_3_2_248_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00592-18"},{"key":"e_1_3_2_249_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01856-17"},{"key":"e_1_3_2_250_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00472-17"},{"key":"e_1_3_2_251_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00206-15"},{"key":"e_1_3_2_252_2","unstructured":"ClinicalTrials.gov. 2017. A study to determine the efficacy safety and tolerability of aztreonam-avibactam (ATM-AVI) \u00b1 metronidazole (MTZ) versus meropenem (MER) \u00b1 colistin (COL) for the treatment of serious infections due to Gram negative bacteria. (REVISIT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03329092."},{"key":"e_1_3_2_253_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz497"},{"key":"e_1_3_2_254_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa021"},{"key":"e_1_3_2_255_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00777-17"},{"key":"e_1_3_2_256_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_2_257_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-19"},{"key":"e_1_3_2_258_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-19"},{"key":"e_1_3_2_259_2","unstructured":"ClinicalTrials.gov. 2019. Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused by Acinetobacter baumannii-calcoaceticus complex (ATTACK). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03894046."},{"key":"e_1_3_2_260_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky522"},{"key":"e_1_3_2_261_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.019"},{"key":"e_1_3_2_262_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02382-18"},{"key":"e_1_3_2_263_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02596-17"},{"key":"e_1_3_2_264_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00432-19"},{"key":"e_1_3_2_265_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.1190"},{"key":"e_1_3_2_266_2","volume-title":"The novel \u03b2-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against extended spectrum \u03b2-lactamase (ESBL)- and carbapenemase-expressing Enterobacteriaceae isolated from recent urinary tract infections, poster 603","author":"McLeod S","year":"2018","unstructured":"McLeod S, Carter N, Hackel M, Badal R, Mueller J, Tommasi R, Miller A. 2018. The novel \u03b2-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against extended spectrum \u03b2-lactamase (ESBL)- and carbapenemase-expressing Enterobacteriaceae isolated from recent urinary tract infections, poster 603. Microbe 2018, Atlanta, GA."},{"key":"e_1_3_2_267_2","volume-title":"The novel beta-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against recent global Enterobacteriaceae isolates from urinary tract infections, poster P1184","author":"Mcleod S","year":"2019","unstructured":"Mcleod S, Moussa S, Huband M, Mueller J, Tommasi R, Miller A. 2019. The novel beta-lactamase inhibitor ETX1317 effectively restores the activity of cefpodoxime against recent global Enterobacteriaceae isolates from urinary tract infections, poster P1184. ECCMID 2019, Amsterdam, Netherlands."},{"key":"e_1_3_2_268_2","volume-title":"Cefpodoxime-ETX1317 susceptibility is unaffected by ceftazidime-avibactam resistance mutations V240G, D179Y and D179Y\/T243M in KPC-3 \u03b2-lactamase","author":"Shapiro A","year":"2019","unstructured":"Shapiro A, Moussa S, Carter N, Gao N, Miller AA. 2019. Cefpodoxime-ETX1317 susceptibility is unaffected by ceftazidime-avibactam resistance mutations V240G, D179Y and D179Y\/T243M in KPC-3 \u03b2-lactamase. Microbe 2019, San Francisco, CA."},{"key":"e_1_3_2_269_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01963-19"},{"key":"e_1_3_2_270_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.1201"},{"key":"e_1_3_2_271_2","volume-title":"In vitro activity of cefepime in combination with VNRX-5133 against meropenem and\/or cefepime resistant clinical isolates of Pseudomonas aeruginosa, abstr 1544","author":"Hackel MA","year":"2018","unstructured":"Hackel MA, Sahm D. 2018. In vitro activity of cefepime in combination with VNRX-5133 against meropenem and\/or cefepime resistant clinical isolates of Pseudomonas aeruginosa, abstr 1544. ECCMID 2019, Madrid, Spain."},{"key":"e_1_3_2_272_2","unstructured":"ClinicalTrials.gov. 2019. Safety and efficacy study of cefepime\/VNRX-5133 in patients with complicated urinary tract infections. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840148."},{"key":"e_1_3_2_273_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.749"},{"key":"e_1_3_2_274_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.745"},{"key":"e_1_3_2_275_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.795"},{"key":"e_1_3_2_276_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00552-20"},{"key":"e_1_3_2_277_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.005"},{"key":"e_1_3_2_278_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.007"},{"key":"e_1_3_2_279_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01541-19"},{"key":"e_1_3_2_280_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.02.004"},{"key":"e_1_3_2_281_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.01.012"},{"key":"e_1_3_2_282_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01814-18"},{"key":"e_1_3_2_283_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S193638"},{"key":"e_1_3_2_284_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.06.002"},{"key":"e_1_3_2_285_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.07.012"},{"key":"e_1_3_2_286_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky107"},{"key":"e_1_3_2_287_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.05.011"},{"key":"e_1_3_2_288_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01587-18"},{"key":"e_1_3_2_289_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.08.009"},{"key":"e_1_3_2_290_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy659"},{"key":"e_1_3_2_291_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky267"},{"key":"e_1_3_2_292_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001859"},{"key":"e_1_3_2_293_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx453"},{"key":"e_1_3_2_294_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0266"},{"key":"e_1_3_2_295_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.02.018"},{"key":"e_1_3_2_296_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx009"},{"key":"e_1_3_2_297_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2017.06.008"},{"key":"e_1_3_2_298_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.05.025"},{"key":"e_1_3_2_299_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00405-16"},{"key":"e_1_3_2_300_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2016.036"},{"key":"e_1_3_2_301_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.06.008"},{"key":"e_1_3_2_302_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz379"},{"key":"e_1_3_2_303_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.001"},{"key":"e_1_3_2_304_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S173804"},{"key":"e_1_3_2_305_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx253"},{"key":"e_1_3_2_306_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02125-17"},{"key":"e_1_3_2_307_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz547"},{"key":"e_1_3_2_308_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0674-4"},{"key":"e_1_3_2_309_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.10.004"},{"key":"e_1_3_2_310_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02048-18"},{"key":"e_1_3_2_311_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.024"},{"key":"e_1_3_2_312_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.913352"},{"key":"e_1_3_2_313_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02841-15"},{"key":"e_1_3_2_314_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"e_1_3_2_315_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_2_316_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.03.021"},{"key":"e_1_3_2_317_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-16"},{"key":"e_1_3_2_318_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky295"},{"key":"e_1_3_2_319_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy492"},{"key":"e_1_3_2_320_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03074-15"},{"key":"e_1_3_2_321_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.001"},{"key":"e_1_3_2_322_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix014"},{"key":"e_1_3_2_323_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"e_1_3_2_324_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105925"},{"key":"e_1_3_2_325_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00072-17"},{"key":"e_1_3_2_326_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1563071"},{"key":"e_1_3_2_327_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0340-0"},{"key":"e_1_3_2_328_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1660772"},{"key":"e_1_3_2_329_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz002"},{"key":"e_1_3_2_330_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"}],"updated-by":[{"DOI":"10.1128\/cmr.00021-21","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000}}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00115-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00115-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T08:24:18Z","timestamp":1645604658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.00115-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":329,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,16]]}},"alternative-id":["10.1128\/CMR.00115-20"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00115-20","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"2020-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00115-20"}}